{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Electronic case report form records will be automatically appended with the identification of', 'the creator, by means of their unique User ID. Specified records will be electronically signed', 'by the Investigator to document his/her review of the data and acknowledgement that the data', \"are accurate. This will be facilitated by means of the Investigator's unique User ID and\", 'password; date and time stamps will be added automatically at the time of electronic', 'signature. If an entry on an eCRF requires change, the correction should be made in', 'accordance with the relevant software procedures. All changes will be fully recorded in a', 'protected audit trail, and a reason for the change will be required.', 'The monitor will review the eCRFs and evaluate them for completeness and consistency.', 'The eCRF will be compared with the source documents to ensure that there are no', 'discrepancies between critical data. All entries, corrections, and alterations are to be made by', 'the responsible Investigator or his/her designee. The monitor cannot enter data in the eCRFs.', 'Once clinical data of the eCRF have been submitted to the central server, corrections to the', 'data fields will be audit trailed, meaning that the reason for change, the name of the person', 'who performed the change, together with time and date will be logged. Roles and rights of', 'the study site staff responsible for entering the clinical data into the eCRF will be determined', 'in advance. If additional corrections are needed, the responsible monitor or Data Manager', 'will raise a query in the EDC application. The appropriate study site staff will answer', 'queries sent to the Investigator. This will be audit trailed by the EDC application meaning', 'that the name of study site staff, time, and date stamp are captured.', 'The eCRF is essentially considered a data entry form and should not constitute the original', '(or source) medical records unless otherwise specified. Source documents are all documents', \"used by the Investigator or hospital that relate to the subject's medical history, that verify the\", 'existence of the subject, the inclusion and exclusion criteria, and all records covering the', \"subject's participation in the study. They include laboratory notes, ECG results, memoranda,\", 'pharmacy dispensing records, subject files, etc.', 'The Investigator is responsible for maintaining source documents. These will be made', 'available for inspection by the monitor at each monitoring visit. The Investigator must', 'submit a completed eCRF for each subject who receives study treatment, regardless of', 'duration. All supportive documentation submitted with the eCRF, such as laboratory or', 'hospital records, should be clearly identified with the study and subject number. Any', 'personal information, including subject name, should be removed or rendered illegible to', 'preserve individual confidentiality.', 'Adverse events and medical history will be coded using the most recent version of the', 'Medical Dictionary for Regulatory Activities (MedDRA). Concomitant medications will be', 'coded using the World Health Organization Drug Dictionary Enhanced (WHO DDE).', 'Amendment 2: 06 March 2019', '121', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '8.2', 'Quality Assurance Audit', 'Study sites, the study database, and study documentation may be subject to a Quality', 'Assurance audit during the course of the study by R-Pharm International or R-Pharm', \"International's designee on behalf of R-Pharm International. In addition, inspections may be\", 'conducted by regulatory bodies at their discretion.', 'Amendment 2: 06 March 2019', '122', 'Confidential']\n\n###\n\n", "completion": "END"}